Genetic disorders and renal cell carcinoma

Urologic Clinics of North America

Volumn 30, Issue 1, 2003, Pages 133-141

  Maranchie, Jodi K ^a   Linehan, W Marston ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGENESIS; CLINICAL FEATURE; FAMILIAL CANCER; FAMILIAL DISEASE; GENETIC DISORDER; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; REVIEW; SCREENING;

CARCINOMA, RENAL CELL; GENES, DOMINANT; GENETIC PREDISPOSITION TO DISEASE; HIPPEL-LINDAU DISEASE; HUMANS; KIDNEY NEOPLASMS; LIGASES; LINKAGE (GENETICS); SYNDROME; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 0037308931     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00120-9     Document Type: Review

References (50)

1. Singh AD, Shields CL, Shields JA. von Hippel-Lindau disease. Surv Ophthalmol 2001;46:117-42.
2. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-91.
3. von-Hippel E. Uber eine sehr seltene erkrankrung der netzhaut. Klinische Boebachtungen Arch Ophthalmol 1904;59:83-106.
4. Lindau A. Studien uber kleinhirncysten bau: pathogenese und beziehungen zur angiomatous retinae. Acta Pathol Microbiol Scand 1926;Supp 1:1-28.
5. Cushing H, Bailey P. Hemangiomas of cerebellum and retina (Lindau's disease), with a report of a case. Arch Ophthalmol 1928;57:447-63.
6. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
7. Niemela M, Lemeta S, Sainio M, et al. Hemangioblastomas of the retina: impact of von Hippel-Lindau disease. Invest Ophthalmol Vis Sci 2000;41:1909-15.
8. Sora S, Ueki K, Saito N, et al. Incidence of von Hippel-Lindau disease in hemangioblastoma patients: the university of Tokyo hospital experience from 1954-1998. Acta Neurochir (Wien) 2001;143:893-6.
9. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
10. Gross DJ, Avishai N, Meiner V, et al. Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Metab 1996;81:147-9.
11. Eisenhofer G, Walther MM, Huynh TT, et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001;86:1999-2008.
12. Zbar B, Kaelin W, Maher E, et al. Third International Meeting on von Hippel-Lindau disease. Cancer Res 1999;59:2251-3.
13. Manski TJ, Heffner DK, Glenn GM, et al. Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997;277:1461-6.
14. Shen T, Zhuang Z, Gersell DJ, et al. Allelic deletion of VHL gene detected in papillary tumors of the broad ligament, epididymis, and retroperitoneum in von Hippel-Lindau disease patients. Int J Surg Pathol 2000;8:207-12.
15. Chauveau D, Duvic C, Chretien Y, et al. Renal involvement in von Hippel-Lindau disease. Kidney Int 1996;50:944-51.
16. Walther MM, Lubensky IA, Venzon D, et al. Prevalence of microscopic lesions in grossly normal renal parenchyma from patients with von Hippel-Lindau disease, sporadic renal cell carcinoma and no renal disease: clinical implications. J Urol 1995;154:2010-4; discussion 2014-5.
17. Herring JC, Enquist EG, Chernoff A, et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol 2001;165:777-81.
18. Pautler SE, Pavlovich CP, Mikityansky I, et al. Retroperitoneoscopic-guided radiofrequency ablation of renal tumors. Can J Urol 2001;8:1330-3.
19. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene [see comments]. Science 1993;260:1317-20.
20. Richards FM, Schofield PN, Fleming S, et al. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 1996;5:639-44.
21. Knudson AG. VHL gene mutation and clear-cell renal carcinomas. Cancer J Sci Am 1995;1:180.
22. Prowse AH, Webster AR, Richards FM, et al. Somatic inactivation of the VHL gene in von Hippel-Lindau disease tumors. Am J Hum Genet 1997;60:765-71.
23. Iliopoulos O, Kibel A, Gray S, et al. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
24. Blankenship C, Naglich JG, Whaley JM, et al. Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 1999;18:1529-35.
25. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
26. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
27. Richards FM, Crossey PA, Phipps ME, et al. Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet 1994;3:595-8.
28. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-23.
29. Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996;33:328-32.
30. Conaway JW, Kamura T, Conaway RC. The elongin BC complex and the von Hippel-Lindau tumor suppressor protein. Biochim Biophys Acta 1998;1377:M49-54.
31. Pause A, Lee S, Worrell RA, et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 1997;94:2156-61.
32. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999;284:455-61.
33. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-7.
34. Koochekpour S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 1999;19:5902-12.
35. Tacchini L, Dansi P, Matteucci E, et al. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 2001;22:1363-71.
36. Pause A, Lee S, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci USA 1998;95:993-8.
37. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998;1:959-68.
38. Bonicalzi ME, Groulx I, de Paulsen N, et al. Role of exon 2-encoded beta-domain of the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2001;276:1407-16.
39. Schmidt L, Li F, Brown RS, et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am 1995;1:191.
40. Podolski J, Byrski T, Zajaczek S, et al. Characterization of a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J Hum Genet 2001;46:685-93.
41. Woodward ER, Clifford SC, Astuti D, et al. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 2000;37:348-53.
42. Zbar B, Tory K, Merino M, et al. Hereditary papillary renal cell carcinoma [see comments]. J Urol 1994;151:561-6.
43. Zhuang Z, Park WS, Pack S, et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet 1998;20:66-9.
44. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
45. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002;25:25.
46. Weirich G, Glenn G, Junker K, et al. Familial renal oncocytoma: clinicopathological study of 5 families. J Urol 1998;160:335-40.
47. Toro JR, Glenn G, Duray P, et al. Birt-Hogg-Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 1999;135:1195-202.
48. Cohen PR, Kurzrock R. Miscellaneous genodermatoses: Beckwith-Wiedemann syndrome, Birt-Hogg-Dube syndrome, familial atypical multiple mole melanoma syndrome, hereditary tylosis, incontinentia pigmenti, and supernumerary nipples. Dermatol Clin 1995;13:211-29.
49. Schmidt LS, Warren MB, Nickerson ML, et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001;69:876-82.
50. Phillips JL, Pavlovich CP, Walther M, et al. The genetic basis of renal epithelial tumors: advances in research and its impact on prognosis and therapy. Curr Opin Urol 2001;11:463-9.